Member Info for sadoldgit

I will point out Billy that whist the development of our 737 is not known to us, there are developments with competitive chk1 inhibitors.

Whilst myself sees 737 out of the equation at the present time l would not rule out ground breaking developments.

In combo therapy not restricted to LDG combo.

Chk1 inhibitors have an all important role to play in DDR hence revival of prexasertib which was discontinued due safety concerns related to effects on heart.

Acrivon have received fast track approval in some types of difficult to treat cancers.

Yes that is correct Krone.

They are claimed on target effects.

Deucravacinib looks good on the chart, but as you know failed to meet its end points in UC an auto I.mune disease, placebo nigh gave a better result.

In Psoriasis mediocre efficacy hence the recent developments of Tyk2 Jak inhibitors.

Ropsacitinib looks to be our biggest threat (Tyk 2 Jak2) inhibitor for Psoriasis should present claims continue into late stage trials.

On top we of this we have hefty long term patent protection.

Regards

Although the claimed selectivity data shows a good profile, Deucravacitinib gave moderate results in Psoriasis and failed to meet its end points in UC.

Being progressed in SLE and may do well.

This is the arena that 1801 is in, with an added advantage of dual inhibition with Jak1.

As for the allosteric Tyk2 inhibition being a claimed regulator of the active site certain Deucravacitinib investigations indicate that this novel compound on its own is not as great as is claimed in marketing data.

Regards

Good morning fearg,

We may be barking up the wrong tree with a buyout.

However, if we look at a couple of events and non events.

Firstly in the progression of 1801 there has been no fund raise, yet at the time if preliminary phase1 data funds could have been raised to cover phase1b to progress in Psoriasis.

Sareum have informed us that the data they have analysed so far and that will include the pharmacodynamics that 1801 may prove to be by conferral best in class with respect to other Tyk2 Jak1 inhibitors.

I would postulate that the analysis will enable Indications to be identified to enter into phase2 trials.

Beprocitinib discontinued in SLE as failed to meet end points l might add.

This is important with respect to commercial valuation of 1801.

Informal discussions are indeed taking place.

Tim has stepped down from CEO that will enable him to concentrate on 1802 development enabling 1802 to enter clinical phase trials.

A big hurdle here as we are first to have Tyk 2 Jak1 on immune oncology. With decent safety profile pretty sure it will put the value within the Deucravacitinib ball park figure should progression run smoothly.

That would give us in a fairly short time span

1801 phase2 in identified indication or indications.

1802 end of preclinical leading to clinical trial most likely phase 1/2, again in a nominated indication.

Due to the similarity of 1801 and 1802 it may well be that phase1 clinical trial would not be required.

At this stage a valuation can be gained to the potential value of the combined potential commercial value of our compounds against a risk factor.

Safety here paramount which we do look rather good at.

In effect the company at this stage will become ripe for a buy out as there will then be the meat on the bones to negotiate.

With regards to 737 that at the moment l feel immaterial as any value assigned to will be dwarfed by the value of our 1801 1802 compounds.

Time scale is a job to put any form of prediction.

At least 3 months l would say from receipt of preliminary data.

October onwards, but this is a very rough estimate. Allow another 6 weeks for writing up of contracts.

Similar timescales l feel applicable to on licence albeit likely to be a tad earlier.

It may well be they have an interested party or parties for 1802 on licence or Co development and in addition interested party in both and in that case a total buyout by this party.

The only people who know what is happening behind closed doors are the BoD and they have been awfully quiet.

As time drags on l feel the fund raise of a dilutive factor is less likely to happen although have obtained funds to add should this prove to be the case.

For sure am feeling confident that the tide is changing.

I will add that l don't believe the company has been approached to be bought out, more than likely an approach for both compounds subject to their progression.

Regards

Fearg absolutely!

They can put 1801 forward into as many Indications as they deem fit.

The only likely competition in this area l believe that may prove better is 1802 as that is now gaining patent protection for immunotherapy.

1802 maybe be better in some Indications along the likes of UC.

Maybe use as back up for 1801.

The important aspect is we have two similar compounds albeit not exact.

We may therefore postulate that the positive data from 1801 will be indicative albeit not 100% in 1802.

If l were a company looking at 1801 l would like to know of a possibility of commercial threat from 1802.

Very similar but not exact, that certainly proves the extent to which Sareum have gone to develop their compounds.

Importance of pharmacodynamic data.

Bare in mind this all.overlap into 1802.

From the extract taken from the RNS, it is evident that Sareum are now in receipt of the pharmacodynamic data as well as the initial availability of the pharmakinetic data.

Pharmakinetic being the effect the body has on the compound and the pharmacodynamics that is the effect the compound has on the body.

To actually release ' could confer significant advantages over ' is indicicative of the confidence that Sareum have.

The proof of the pudding is in the eating so as to speak.

As for Indications to be trialled, very interesting.

Are we better than the rest in Psoriasis and continue or do Tim and Co push for a different indication with less competiveness?

Next stage of news l believe the conformation of full data package for entry into an indication or indications.

As ATMKD stated we have patent protection in all major territories. Of paramount importance!

I would hazard a guess that any interested party will need to know Indications to be entered into clinical trial and confirmation following conferral, prior to any signing of a contract of onlicence or similar, prior to any release of a long awaited, transformational RNS.

We are pleased to extend the patent protection for SDC-1801 on the back of the encouraging data from our Phase 1a trial, indicating our inhibitor could confer significant advantages over other TYK2/JAK1 kinase inhibitors.

If more than one interested party then we do indeed have game on.

We do need an involvement or agreement with a well heeled pharma in whatever form.

Nothing is for certain of course. No guarantee.

Risk v reward.

Regards

Of relevance l believe is the paragraph below.

Clearly from this they have full data in their possession.

A good indication but nothing guaranteed.

A reassuring degree of confidence here.

'Dr John Reader, Sareum's Chief Scientific Officer, commented: "We are pleased to extend the patent protection for SDC-1801 on the back of the encouraging data from our Phase 1a trial, indicating our inhibitor could confer significant advantages over other TYK2/JAK1 kinase inhibitors. We remain motivated in progressing SDC-1801 through clinical development to develop new therapeutics for autoimmune diseases and cancers."'

Regards

Busy at moment, but will get back later 007.

I would say you are spot on there Bobbler.

Definition regarding analogue

'noun: analogue; plural noun: analogues; noun: analog; plural noun: analogs

a person or thing seen as comparable to another.

"an interior analogue of the exterior world"

Chemistry

a compound with a molecular structure closely similar to that of another.

"thioacids are sulphur analogues of oxyacids"

Indicative of inclusion of 1802.

No need for separate similar Patent for 1802.

Regards

Worth a read

https://exitwise.com/blog/biotech-valuation

Good morning funnyguy.

I accept your opinions as they are after all only that, an opinion and your opinion.

However, l don't agree with your opinions especially regards to placing values on the company.

Pre RF finance we have gone from 70 odd million down to a current market cap of 30 million.

The phase 1a trial has been successful ie with no serious adverse effects reported at what is considered as therapeutic doses.

To establish a value for 1801 the potential Indications along with possible revenue gain need to be established and yes subject to a probability of success.

1801 in preclinical had a value and that value would have increased by success in phase1a.

1802 in this scenario definitely has a value albeit coming to end of preclinical.

As above with 1801, 1802 can have a value placed on it dependant on Indications and potential share of the roadside market in these Indications when known.

In preclinical, drug description provides information to potential success in differing Indications with assigned patent protection.

1802 in the description of application can be used as a supporting therapy with other inhibitors such as, but not limited to but incudes PD-1 inhibitors.

All this of course is subject to probability of success and indeed this is the risk factor.

Most oncology drugs are far more effective when used in combo therapy.

A question to you funnyguy.

What is the significance of in combo therapy especially with regards to monoclonal antibodies and kinase inhibitors?

To conclude it is a very complex issue with regards to assigning a value to a potential drug candidate.

As a plus side, in combo therapy can be patented thus enabling a source of revenue from compounds otherwise open to generic manufacture.

With regards to 737 l will remind you that is has been onlicenced.

I will agree we have had no updates.

Chk1 inhibitors are being progressed in the field of oncology even to the point of recent new inhibitors Bebt 260 being one.

Vital in control of the DNA Damage Repair pathway but must prove safety with careful selection of combo partners.

Acrivon were licensed prexasertib that had been shelved due to unacceptable myocardial events and indeed were oversubscribed in raising just over 100 million dollars to progress.

Indeed fast tracked to treat areas with an urgent unmet need.

You have your opinions and l have mine.

A couple of bloomers dropped by Sareum as l see it it.

CTA for 1801 they attempted themselves.

Raising of funds via equity release. A good idea at the time but suffered by the antics of a company hell bent on destroying the market cap value of a company.

A top notch scientist foes not make a top notch CEO where finance or licensing deals are concerned.

Regards and have a good day

Https://seekingalpha.com/news/4144975-merck-stops-two-more-cancer-trials-over-poor-results

That is a tall question fearg.

Many aspects here involved.

Up front payment one aspect.

Milestone payments

Sufficient funding if 50 m upfront was paid enabling progress 1802.

No raising of funds worries for a while.

Market sentiment.

As we sit at the moment further forward with a 39 odd million market cap whereas a year ago we were over 100p.

Grossly undervalued at the moment despite the yellow dot indicating a fair price.

So much depends on the finalised data.

Aspect of 1801 safety whilst not a concern to its progression will need top end results.

Importantly, which Indications do Sareum intend to progress 1801.

With a 50 million upfront payment would suggest a figure close to 200 million or roundabouts.

737 we have had no news of progression development on that front at least a jump of 10p maybe as high as 20p dependant of course on news.

1802 if were to onlicence at end of preclinical and subject to data results likely to be around 200 to 300 million up front with milestone payments taking it to over a billion. That of course being subject to 1802 being potentially as good as we are led to believe.

Tis my gut feeling only but minimum of 200 million which is not that far from the 179p SP forecast.

Sareum have very little else remaining in the pipeline and as such l do not foresee Tim becoming involved in going shopping for more compounds as he stated around 2021 should a company choose to pay the price for both 1801 and 1802.

Company now sits as a ripe target for buyout irrespective of 737 outcome.

Dependant on what stage 1802 gets developed to prior to on licence or sale of somesort will also have impact on share price.

Good phase 2 results on 1802 with its potential 500 to 750 million.

Tim.will have better idea than us with regards to value, maybe he wants more than what companies are prepared to pay at the current time.

I will stick with my gut feeling of 200 million should a 50 million upfront be paid.

Depending on successful development of 1802 company worth anything up to 1 billion plus.

Not going to happen overnight and we are at the moment continuing to burn through albeit at a low rate the funds we have and including in the burn the tax relief which l believe will be in September.

Long post from me as usual.

My opinions only and not to be taken as any advice.

There is indeed risk as well as reward to which many of us are aware.

No problem Laz.

Easily done.

Would be interesting to know from whence they derived this figure.

Happy to forecast 179 p per share but also complicit in pushing it to drop to 10p a while back.

PH advise on RF debt equity raise?

Were they looking for SAR to financially fail and then organise a sell off to an interested 3rd party?

200 million for the whole caboodle is basically giving it away.

Good afternoon Lazarus, target shown higher in link below.

https://fintel.io/sfo/gb/sar#:~:text=The%20average%20one%2Dyear%20price,projected%20earnings%20and%20historical%20earnings.

I will add that preliminary data indicates ok to enter later stage of trial.

Sareum could have raised funding via share dilution to enable a phase 2a trial, but as time passes it is looking extremely likely of a non dilutive form of raising funds.

In addition if an on licence is seen as the way forward details and the data relating to potential Indications need to be realised.

Negotiations take time as does setting up of contracts if this is indeed the case.

I would not rule a complete takeover out.

Tim is now able to concentrate on pipeline.

This will include in selecting and developing a candidate for phase trials as that logically the next step.

He will be far more adept at concentrating on this role as opposed to concerns of funding or licensing. After all he is a well accomplished chemical scientist.

What are your opinions on that which l have stated funnyguy?

The silence does not mean there is nothing going on in the background, it takes as long as it takes.

Interesting HbD.

4 of those mentioned are sareum developed compounds too!

As l said Surfie1961 you have posted nothing of any benefit here to those invested, or Sareum, indeed, only detriment.

My posts have mainly been optimistic but not always.

I have been here since 2012.

Was optimistic when we stood at 0.25p pre consolidation and we reached a few years later at 9p old money.

Likewise, would you also wish to see a link between my optimistic posts from a few years ago and the corresponding 3,600 % SP increase.

Highly unlikely anyone would choose to invest here after reading your posts with the exception of those that short a share.

As much as people like to blame the BoD the financial markets have suffered considerably since Feb 2022.

Manufacturers of military equipment and the likes of Blackrock have made billions upon billions.

Investment has become difficult in some market sectors and bio pharma being one.

Whilst l will admit the BoD have made some poor decisions they have not compromised on their compound development.

Are you able to understand this?

The market at the moment is very competitive.

Sareum will need to fit in.

Have a good day.

I need to shorten my posts Warthog4.

Surfie1961.

No informative post ever from you Surfie1961 that is relevant, beneficial or in anyway constructive from you about Sareum, or those invested.

That is a fact.

Have a good day.